Search

The National Center for Tumor Diseases – NCT Heidelberg was founded as an exceptional alliance between the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKL-HD), the Heidelberg Medical Faculty, and German Cancer Aid (Deutsche Krebshilfe). The NCT MASTER project is situated at the interface of cancer genomics and clinical oncology to provide comprehensive molecular profiling to selected patients with unmet medical need, and to evaluate the utility of such an approach for informing choices regarding targeted therapy based on the molecular characteristics of the individual cancer. This multidisciplinary initiative has implemented a standardized workflow for patient selection, sample processing, molecular and bioinformatic analysis, technical validation of individual findings, and reporting of results through a dedicated molecular tumor board.

This presentation provides a philosophical introduction into the multilayered field of Bioethics. Firstly, it clarifies the somewhat confusing notion of "Bioethics", and then unfolds the key questions that bioethical debate faces today. The following third step discusses five obstacles to a broader discussion and possible solution of those bioethical problems – and gives four concluding hints to what needs to change in order to develop a more intense and open dialogue on those important challenges. PICTURE: Anna Boksa, Anja.

Today we are confronted with a growing loss of biodiversity. All of us agree that we must do something to save the biodiversity. In his lecture, Prof. Hager focuses on the question what is the task of the law in this context. His lecture has three parts. In the first part, he discusses a famous case on biodiversity. The case opens the way to the second part where the efficiency of environmental law is discussed. In the third part, Prof. Hager outlines the structure of a modern ecological environmental law.

Cancer is the second leading cause of death worldwide. President Roosevelt first established the National Cancer Institute and, later, President Nixon signed into law the National Cancer Act of 1971 to make the “Conquest of Cancer […] a national crusade”, declaring the “War on Cancer.” The worldwide research efforts focusing on the molecular and cellular biology and clinical spectrum of cancer have led to a better understanding of cancer as an acquired genetic disease, as well as to the importance of evolutionary processes in carcinogenesis and the clinical course of cancer. Based on these insights, novel therapeutic concepts have been developed and are already significantly improving the outlook for patients with cancer. PICTURE: Ludwig Köhler, Sculptures.

In this article, JOSHA's Editor Stephan Seiler reviews the arts exhibition that took place during the Symposium "Science, Ethics and Arts". Herein he presents the work of four artists with four different approaches: the photographer Anna Boksa, the young painter Giulia Musella, the internationally well-known artist John Tun Sein, and the sculptor Ludwig Köhler.

The “socially valuable knowledge” (SVK) principle has been widely acknowledged as one of the most important guiding principles for research involving human subjects. In this presentation, Felicitas Holzer reconstructs the main arguments of the discussion between defenders and debunkers of the SVK principle and offer a third way to consider the social value of knowledge in research studies. PICTURE: John Tun Sein, Untitled 2016.

In this presentation, Dr. Mastroleo defends the view that clinical innovation should be understood, following Levine, as non-validated medical practice. Moreover, he argues that if this is the correct interpretation of clinical innovation this implies that the ethics of clinical innovation are different from (some) clinical research and validated medical practice. PICTURE: Anna Boksa, "Damian". Addendum April 13, 2019: As one of the world experts in ethics of non-validated practice I think you would enjoy watching this discussion at the NIH: Sugarman, J. (2017). NIH VideoCast - Ethics Rounds: Offering Patients Innovative Therapy: When Is It a Good Idea? Retrieved May 24, 2018, from https://videocast.nih.gov/summary.asp?Live=21779&bhcp=1

In this presentation, Dr. Vasen explores the regulatory developments in stem cell medicine in the main national jurisdictions. He claims that the field is undergoing a process of diversification and indetify three pathways of regulatory development: international harmonization, "double discourse" and alter-standardization. The presentation is based on previous work published together with Achim Rosemann, Gabriela Bortz, and Margaret Sleeboom-Faulkner. PICTURE: Giulia Musella, Woman on a flower meadow.

The current issue of the Journal of Science, Humanities and Arts brings exciting news to our readers along with eight novel contributions to the scientific, humanities, and arts fields. We dedicated this issue mainly to philosophy, ethics, law, and arts, which is mainly focused on the interdisciplinary relationship between these fields. We expect that you will enjoy it and we are already looking forward to what the next JOSHA articles will bring to our Science, Humanities, and Arts community.

The School of Pharmacy and Biochemistry of the University of Buenos Aires hosts the third International Congress on Translational Medicine on November 21st and 22nd, under the auspices of the German Embassy in Buenos Aires and the Asociacion de Universidades Grupo Montevideo. The International Congress will be held in the context of the International Master Program in Biomedical Sciences (IMBS) Cooperation, a German-Argentinean Study Program from the Universities of Freiburg and Buenos Aires which is currently being extended to the University of Montevideo, Uruguay. The Master Program was launched in 2008 and has already paved the way for many graduates who joined academic and professional careers. A broad range of topics in the fields of Molecular Biology and Medicine as well as Microsystems and Bioethics will be covered by the two-day Congress. Moreover, Prof. Dr.